PDCD1 and glioma: Subsequently, we investigated whether PDIA5 could predict glioma patients’ responses to checkpoint inhibitor immunotherapy in anti-CTLA-4 and anti-PD-1 based on CGGA and TCGA datasets, and found that compared with low PDIA5 group, high PDIA5 group was expected to respond better to immunotherapies (Figure 7C).